11 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
to 2017 in positions of escalating responsibility, where he supported Amgen’s portfolio of products through partnerships and life cycle management. Mr
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
with University College London Expand obe-cel opportunity in B cell malignancies, autoimmune diseases & life cycle strategy – SLE – B-NHL indications – Bi-specific
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
13 Feb 24
Regulation FD Disclosure
4:06pm
malignancies, autoimmune diseases & life cycle strategy SLE B-NHL indications Bi-specific therapies (CD19 /CD22; CD19/BCMA) Expand to additional … Long-standing academic collaboration with University College London Expand obe-cel opportunity in B cell malignancies, autoimmune diseases & life cycle strategy
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
11 Dec 23
Regulation FD Disclosure
8:31am
and platform technology Expand obe-cel opportunity in B cell malignancies, autoimmune diseases & life cycle strategy – SLE – B-NHL indications – Bi
6-K
EX-1
AUTL
Autolus Therapeutics plc
1 Jul 22
Current report (foreign)
5:15pm
is in the development stage of its life cycle and is investing in research and development, with no operating income to date.
We determined materiality
6-K
EX-99.1
llxnxzt1vuioc1v1mhxu
15 Nov 21
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
12:00am
6-K
EX-99.4
rgnokp9yewi8myant
8 Nov 21
Securities Purchase Agreement
5:28pm
6-K
EX-1
9pf5 zqn47bsm
30 Jun 21
Annual Report and Accounts
6:05am
6-K
EX-1
tobe8 7fnfwkr
26 May 20
Current report (foreign)
4:31pm
6-K
EX-1
7wmmtk qpwg
15 Mar 19
Annual Report and Accounts
5:26pm
- Prev
- 1
- Next